Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$0.38 -7.8%	$0.72	$0.29 ▼ $1.65	$29.85M	2.09	13.04 million shs	814,430 shs
CTOR Citius Oncology	$2.06 -6.8%	$2.26	$0.55 ▼ $49.00	$161.44M	3.01	2.53 million shs	608,706 shs
KRRO Korro Bio	$13.85 -7.4%	$13.41	$10.29 ▼ $98.00	$130.06M	2.51	119,372 shs	144,034 shs
NKTX Nkarta	$2.12 -2.3%	$1.87	$1.31 ▼ $6.63	$150.43M	0.72	567,093 shs	472,909 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	0.00%	-22.75%	-53.27%	-55.84%	-66.31%
CTOR Citius Oncology	0.00%	+4.57%	-61.28%	+122.70%	+205,999,900.00%
KRRO Korro Bio	0.00%	-13.49%	+7.36%	-33.83%	-70.25%
NKTX Nkarta	0.00%	-1.85%	+20.80%	+1.44%	-67.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	2.3817 of 5 stars	4.1	5.0	0.6	0.0	0.0
CTOR Citius Oncology	1.3484 of 5 stars	3.0	0.0	1.8	1.7	0.0
KRRO Korro Bio	1.3282 of 5 stars	3.6	1.0	0.6	0.0	0.6
NKTX Nkarta	2.3202 of 5 stars	3.6	0.0	4.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	2.17	Hold	$4.20	993.47% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	45.63% Upside
KRRO Korro Bio	3.29	Buy	$102.43	639.56% Upside
NKTX Nkarta	3.13	Buy	$14.33	576.10% Upside

Current Analyst Ratings Breakdown

Latest CLSD, CTOR, NKTX, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$1.66M	17.98	N/A	N/A	($0.51) per share	-0.75
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
KRRO Korro Bio	$2.27M	57.29	N/A	N/A	$17.12 per share	0.81
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-53.88%	-18.86%	N/A
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)

Latest CLSD, CTOR, NKTX, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	N/A	N/A	N/A	$0.41 million	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	3.19	3.19
CTOR Citius Oncology	0.11	0.36	0.05
KRRO Korro Bio	N/A	9.41	9.41
NKTX Nkarta	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
CTOR Citius Oncology	70.52%
KRRO Korro Bio	13.18%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	6.20%
CTOR Citius Oncology	4.57%
KRRO Korro Bio	4.60%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
NKTX Nkarta	140	70.96 million	65.00 million	Optionable

CLSD, CTOR, NKTX, and KRRO Headlines

Recent News About These Companies

Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) PT at $14.33

August 2 at 2:37 AM | americanbankingnews.com

Monaco Asset Management SAM Invests $1.50 Million in Nkarta, Inc. (NASDAQ:NKTX)

July 31 at 6:50 AM | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

July 30, 2025 | marketbeat.com

Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series

July 23, 2025 | tmcnet.com

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

July 23, 2025 | globenewswire.com

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

July 22, 2025 | seekingalpha.com

Peapod Lane Capital LLC Purchases New Stake in Nkarta, Inc. (NASDAQ:NKTX)

July 10, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by Brokerages

July 5, 2025 | marketbeat.com

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

June 27, 2025 | uk.finance.yahoo.com

Nkarta, Inc. (NKTX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 7, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.comQ

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

William Blair Downgrades Nkarta (NKTX)

May 15, 2025 | msn.com

Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 15, 2025 | finanznachrichten.de

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025 | globenewswire.com

Nkarta (NKTX) Upgraded to Buy: Here's Why

April 14, 2025 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?
By Jeffrey Neal Johnson | July 14, 2025
View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?
3 Stocks Flying Under the S&P 500 Radar
By Chris Markoch | July 25, 2025
View 3 Stocks Flying Under the S&P 500 Radar
3 Stocks Poised to Benefit From the "Big Beautiful Bill"
By Nathan Reiff | July 7, 2025
View 3 Stocks Poised to Benefit From the "Big Beautiful Bill"
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
By Gabriel Osorio-Mazilli | July 23, 2025
View Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

CLSD, CTOR, NKTX, and KRRO Company Descriptions

Clearside Biomedical NASDAQ:CLSD

$0.38 -0.03 (-7.80%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+2.58%)

As of 08/1/2025 07:59 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Citius Oncology NASDAQ:CTOR

$2.06 -0.15 (-6.79%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.18 +0.12 (+6.02%)

As of 08/1/2025 08:00 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Korro Bio NASDAQ:KRRO

$13.85 -1.11 (-7.42%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.84 -0.01 (-0.07%)

As of 08/1/2025 04:10 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$2.12 -0.05 (-2.30%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.04 (-2.12%)

As of 08/1/2025 07:45 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time